Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 29;19:69. doi: 10.1186/s40644-019-0253-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 7 — A 42-year-old woman with suspected primary benign bone tumors of the pelvis. a Preoperative axial CT image demonstrates osteolytic bone destruction in the fifth lumbar vertebra (yellow arrow) and expansile, osteolytic bone destruction with cortical interruption (yellow arrow). b-c The intraprocedural axial CT image (using bone windows) shows that the biopsy needle is inserted into the bone lesion (yellow arrow). The histopathologic biopsy results (d: hematoxylin and eosin, original magnification 40×, e: hematoxylin and eosin, original magnification 100×) diagnosed the bone lesion as a giant-cell tumor. Finally, the surgical histopathology results (f: hematoxylin and eosin, original magnification 40×) of the bone lesion confirmed the diagnosis of a giant-cell tumor. Immunohistochemistry showed that the monocyte-like cells were CD163 (+), CD68 (KP1) (+), Ki-67 (positive rate approximately 40%), p63 (+), and SMA (−)